A previous study using B16 melanoma and J558 plasmacytoma mouse syngeneic models found that CD200 expression could inhibit tumor growth and metastasis by shaping the TME [17,20], while another indicated that CD200R1-deficient mice display accelerated CD200+ B16 melanoma growth [16]. Here, CD200 is linked to plasmacytoma.